• レポートコード:MRC23Q36726 • 出版社/出版日:QYResearch / 2023年3月 • レポート形態:英文、PDF、89ページ • 納品方法:Eメール(2-3日) • 産業分類:医薬品 |
Single User | ¥435,000 (USD2,900) | ▷ お問い合わせ |
Enterprise License | ¥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは世界の二価ヒトパピローマウイルスワクチン市場について調査・分析し、世界の二価ヒトパピローマウイルスワクチン市場概要、メーカー別競争状況、地域別市場規模、タイプ別セグメント分析(HPV16、HPV18)、用途別セグメント分析(9~16歳、16~20歳、20~26歳、26~45歳)、主要企業のプロファイル、市場動向などに関する情報を掲載しています。主要企業としては、Merck & Co., Inc.、GSK、INNOVAX、ZSSW、HUMANWELL HEALTHCARE、WALVAX、Serum Institute of Indiaなどが含まれています。 世界の二価ヒトパピローマウイルスワクチン市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX%です。COVID-19とロシア・ウクライナ戦争の影響は、二価ヒトパピローマウイルスワクチン市場規模を推定する際に考慮しました。本レポートは、二価ヒトパピローマウイルスワクチンの世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、二価ヒトパピローマウイルスワクチンに関するビジネス上の意思決定に役立てることを目的としています。 ・二価ヒトパピローマウイルスワクチン市場の概要 - 製品の定義 - 二価ヒトパピローマウイルスワクチンのタイプ別セグメント - 世界の二価ヒトパピローマウイルスワクチン市場規模:タイプ別分析(HPV16、HPV18) - 二価ヒトパピローマウイルスワクチンの用途別セグメント - 世界の二価ヒトパピローマウイルスワクチン市場規模:用途別分析(9~16歳、16~20歳、20~26歳、26~45歳) - 世界の二価ヒトパピローマウイルスワクチン市場規模予測(2018年-2029年) - 二価ヒトパピローマウイルスワクチンの平均価格推移(2018年-2029年) - 前提条件と制限事項 ・メーカー別競争状況 - メーカー別市場シェア - 世界の主要メーカー、業界ランキング分析 - メーカー別平均価格 - 二価ヒトパピローマウイルスワクチン市場の競争状況およびトレンド ・二価ヒトパピローマウイルスワクチンの地域別市場規模 - 北米の二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - アメリカの二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - ヨーロッパの二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - アジア太平洋の二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - 中国の二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - 日本の二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - 韓国の二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - インドの二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - オーストラリアの二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - 中南米の二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) - 中東・アフリカの二価ヒトパピローマウイルスワクチン市場規模(2018年-2029年) ・タイプ別セグメント:HPV16、HPV18 - 世界の二価ヒトパピローマウイルスワクチンのタイプ別販売量(2018年-2023年) - 世界の二価ヒトパピローマウイルスワクチンのタイプ別売上(2018年-2023年) - 世界の二価ヒトパピローマウイルスワクチンのタイプ別価格 ・用途別セグメント:9~16歳、16~20歳、20~26歳、26~45歳 - 世界の二価ヒトパピローマウイルスワクチンの用途別販売量(2018年-2023年) - 世界の二価ヒトパピローマウイルスワクチンの用途別売上(2018年-2023年) - 世界の二価ヒトパピローマウイルスワクチンの用途別価格 ・主要企業のプロファイル:企業情報、事業概要、売上、製品ポートフォリオ、動向 Merck & Co., Inc.、GSK、INNOVAX、ZSSW、HUMANWELL HEALTHCARE、WALVAX、Serum Institute of India ・産業チェーンと販売チャネルの分析 - 二価ヒトパピローマウイルスワクチン産業チェーン分析 - 二価ヒトパピローマウイルスワクチンの主要原材料 - 二価ヒトパピローマウイルスワクチンの販売チャネル - 二価ヒトパピローマウイルスワクチンのディストリビューター - 二価ヒトパピローマウイルスワクチンの主要顧客 ・二価ヒトパピローマウイルスワクチン市場ダイナミクス - 二価ヒトパピローマウイルスワクチンの業界動向 - 二価ヒトパピローマウイルスワクチン市場の成長ドライバ、課題、阻害要因 ・調査成果および結論 ・調査方法とデータソース |
Highlights
The global Bivalent Human Papillomavirus Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Bivalent Human Papillomavirus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Bivalent Human Papillomavirus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Bivalent Human Papillomavirus Vaccine include Merck & Co., Inc., GSK, INNOVAX, ZSSW, HUMANWELL HEALTHCARE, WALVAX and Serum Institute of India, etc. in 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Bivalent Human Papillomavirus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bivalent Human Papillomavirus Vaccine.
The Bivalent Human Papillomavirus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Bivalent Human Papillomavirus Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bivalent Human Papillomavirus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Merck & Co., Inc.
GSK
INNOVAX
ZSSW
HUMANWELL HEALTHCARE
WALVAX
Serum Institute of India
Segment by Type
HPV16
HPV18
Segment by Application
9-16 Years Old
16-20 Years Old
20-26 Years Old
26-45 Years Old
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Bivalent Human Papillomavirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Bivalent Human Papillomavirus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
1 Bivalent Human Papillomavirus Vaccine Market Overview
1.1 Product Overview and Scope of Bivalent Human Papillomavirus Vaccine
1.2 Bivalent Human Papillomavirus Vaccine Segment by Type
1.2.1 Global Bivalent Human Papillomavirus Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 HPV16
1.2.3 HPV18
1.3 Bivalent Human Papillomavirus Vaccine Segment by Application
1.3.1 Global Bivalent Human Papillomavirus Vaccine Market Value by Application: (2023-2029)
1.3.2 9-16 Years Old
1.3.3 16-20 Years Old
1.3.4 20-26 Years Old
1.3.5 26-45 Years Old
1.4 Global Bivalent Human Papillomavirus Vaccine Market Size Estimates and Forecasts
1.4.1 Global Bivalent Human Papillomavirus Vaccine Revenue 2018-2029
1.4.2 Global Bivalent Human Papillomavirus Vaccine Sales 2018-2029
1.4.3 Global Bivalent Human Papillomavirus Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bivalent Human Papillomavirus Vaccine Market Competition by Manufacturers
2.1 Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Bivalent Human Papillomavirus Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Bivalent Human Papillomavirus Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Bivalent Human Papillomavirus Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bivalent Human Papillomavirus Vaccine, Product Type & Application
2.7 Bivalent Human Papillomavirus Vaccine Market Competitive Situation and Trends
2.7.1 Bivalent Human Papillomavirus Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bivalent Human Papillomavirus Vaccine Players Market Share by Revenue
2.7.3 Global Bivalent Human Papillomavirus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bivalent Human Papillomavirus Vaccine Retrospective Market Scenario by Region
3.1 Global Bivalent Human Papillomavirus Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bivalent Human Papillomavirus Vaccine Global Bivalent Human Papillomavirus Vaccine Sales by Region: 2018-2029
3.2.1 Global Bivalent Human Papillomavirus Vaccine Sales by Region: 2018-2023
3.2.2 Global Bivalent Human Papillomavirus Vaccine Sales by Region: 2024-2029
3.3 Global Bivalent Human Papillomavirus Vaccine Global Bivalent Human Papillomavirus Vaccine Revenue by Region: 2018-2029
3.3.1 Global Bivalent Human Papillomavirus Vaccine Revenue by Region: 2018-2023
3.3.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Region: 2024-2029
3.4 North America Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.4.1 North America Bivalent Human Papillomavirus Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bivalent Human Papillomavirus Vaccine Sales by Country (2018-2029)
3.4.3 North America Bivalent Human Papillomavirus Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.5.1 Europe Bivalent Human Papillomavirus Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bivalent Human Papillomavirus Vaccine Sales by Country (2018-2029)
3.5.3 Europe Bivalent Human Papillomavirus Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Bivalent Human Papillomavirus Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bivalent Human Papillomavirus Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Bivalent Human Papillomavirus Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.7.1 Latin America Bivalent Human Papillomavirus Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bivalent Human Papillomavirus Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Bivalent Human Papillomavirus Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Bivalent Human Papillomavirus Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Bivalent Human Papillomavirus Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bivalent Human Papillomavirus Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bivalent Human Papillomavirus Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bivalent Human Papillomavirus Vaccine Sales by Type (2018-2029)
4.1.1 Global Bivalent Human Papillomavirus Vaccine Sales by Type (2018-2023)
4.1.2 Global Bivalent Human Papillomavirus Vaccine Sales by Type (2024-2029)
4.1.3 Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Type (2018-2029)
4.2.1 Global Bivalent Human Papillomavirus Vaccine Revenue by Type (2018-2023)
4.2.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Type (2024-2029)
4.2.3 Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Bivalent Human Papillomavirus Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bivalent Human Papillomavirus Vaccine Sales by Application (2018-2029)
5.1.1 Global Bivalent Human Papillomavirus Vaccine Sales by Application (2018-2023)
5.1.2 Global Bivalent Human Papillomavirus Vaccine Sales by Application (2024-2029)
5.1.3 Global Bivalent Human Papillomavirus Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Application (2018-2029)
5.2.1 Global Bivalent Human Papillomavirus Vaccine Revenue by Application (2018-2023)
5.2.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Application (2024-2029)
5.2.3 Global Bivalent Human Papillomavirus Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Bivalent Human Papillomavirus Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck & Co., Inc.
6.1.1 Merck & Co., Inc. Corporation Information
6.1.2 Merck & Co., Inc. Description and Business Overview
6.1.3 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Product Portfolio
6.1.5 Merck & Co., Inc. Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Bivalent Human Papillomavirus Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 INNOVAX
6.3.1 INNOVAX Corporation Information
6.3.2 INNOVAX Description and Business Overview
6.3.3 INNOVAX Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 INNOVAX Bivalent Human Papillomavirus Vaccine Product Portfolio
6.3.5 INNOVAX Recent Developments/Updates
6.4 ZSSW
6.4.1 ZSSW Corporation Information
6.4.2 ZSSW Description and Business Overview
6.4.3 ZSSW Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 ZSSW Bivalent Human Papillomavirus Vaccine Product Portfolio
6.4.5 ZSSW Recent Developments/Updates
6.5 HUMANWELL HEALTHCARE
6.5.1 HUMANWELL HEALTHCARE Corporation Information
6.5.2 HUMANWELL HEALTHCARE Description and Business Overview
6.5.3 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Product Portfolio
6.5.5 HUMANWELL HEALTHCARE Recent Developments/Updates
6.6 WALVAX
6.6.1 WALVAX Corporation Information
6.6.2 WALVAX Description and Business Overview
6.6.3 WALVAX Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 WALVAX Bivalent Human Papillomavirus Vaccine Product Portfolio
6.6.5 WALVAX Recent Developments/Updates
6.7 Serum Institute of India
6.6.1 Serum Institute of India Corporation Information
6.6.2 Serum Institute of India Description and Business Overview
6.6.3 Serum Institute of India Bivalent Human Papillomavirus Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Serum Institute of India Bivalent Human Papillomavirus Vaccine Product Portfolio
6.7.5 Serum Institute of India Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bivalent Human Papillomavirus Vaccine Industry Chain Analysis
7.2 Bivalent Human Papillomavirus Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bivalent Human Papillomavirus Vaccine Production Mode & Process
7.4 Bivalent Human Papillomavirus Vaccine Sales and Marketing
7.4.1 Bivalent Human Papillomavirus Vaccine Sales Channels
7.4.2 Bivalent Human Papillomavirus Vaccine Distributors
7.5 Bivalent Human Papillomavirus Vaccine Customers
8 Bivalent Human Papillomavirus Vaccine Market Dynamics
8.1 Bivalent Human Papillomavirus Vaccine Industry Trends
8.2 Bivalent Human Papillomavirus Vaccine Market Drivers
8.3 Bivalent Human Papillomavirus Vaccine Market Challenges
8.4 Bivalent Human Papillomavirus Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer